Effects of lipopolysaccharide and phenylbutazone on gastric contents in the horse.
BACKGROUND
Endotoxaemia causes a disruption of gastrointestinal motility in the horse but there is no information on its effects on gastric secretion. Lipopolysaccharide (LPS) administration is known to affect gastric secretion in other species.


OBJECTIVE
That LPS, a toxic component of Gram-negative bacteria, would reduce gastric acid secretion and that pretreatment with phenylbutazone (PBZ) would block the effects of LPS.


METHODS
The effects of LPS and PBZ on gastric contents were investigated in fasted, mature horses, with permanent gastric cannulae. Horses were pretreated with either saline or PBZ 15 mins before a 60 min infusion of either LPS or saline. Gastric contents were collected at 15 min intervals for 3 h, beginning 15 mins after the start of the LPS or saline infusion.


RESULTS
Lipopolysaccharide significantly decreased gastric acid output, [K+] and potassium output and increased [Na+] and sodium output. Phenylbutazone did not affect basal gastric acid secretion but decreased LPS-induced changes in the secreted volume, [Na+] and sodium output.


CONCLUSIONS
This study provides evidence that LPS affects gastric acid secretion in the horse and that these LPS-induced changes are mediated, in part, by prostaglandins.


CONCLUSIONS
Lipopolysaccharide administration can induce changes in the composition of gastric contents in the horse but further work is needed to determine the source of these changes.
Doherty
T J
TJ
College of Veterinary Medicine, PO Box 1071, The University of Tennessee, Knoxville, Tennessee 37901, USA.
Andrews
F M
FM
Blackford
J T
JT
Rohrbach
B W
BW
Sandin
A
A
Saxton
A M
AM
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005766:Gastrointestinal Contents / Q000737:chemistry / Q000187:drug effects*; D006736:Horses / Q000502:physiology*; D006863:Hydrogen-Ion Concentration; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology*; D011188:Potassium / Q000378:metabolism; D011897:Random Allocation; D012964:Sodium / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008070:Lipopolysaccharides; D012964:Sodium; D010653:Phenylbutazone; D011188:Potassium